Source:http://linkedlifedata.com/resource/pubmed/id/20458483
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-5-21
|
| pubmed:abstractText |
The advance of medical treatment in renal cell carcinoma (RCC) has fostered the development of diverse continuous oral therapies with tyrosine kinase inhibitors (TKI), among these sunitinib remains the mainstay of therapy for most of the patients. Based on its clinical activity, disease control over a period of 11 months can be expected with sunitinib treatment. Given this prolonged period of exposure to sunitinib, adverse events tend to reoccur and can possibly decrease the quality of life in our patients. Hence, development of modalities to detect, treat and cope with such adverse events has become a major focus for physicians and patients. Today, numerous publications address these questions and offer advice from experienced centers. However, these reviews summarize single or oligo-center experiences.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1433-8726
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
343-51
|
| pubmed:meshHeading |
pubmed-meshheading:20458483-Carcinoma, Renal Cell,
pubmed-meshheading:20458483-Consensus,
pubmed-meshheading:20458483-Diarrhea,
pubmed-meshheading:20458483-Dose-Response Relationship, Drug,
pubmed-meshheading:20458483-Drug Administration Schedule,
pubmed-meshheading:20458483-Early Detection of Cancer,
pubmed-meshheading:20458483-Evidence-Based Medicine,
pubmed-meshheading:20458483-Fatigue,
pubmed-meshheading:20458483-Female,
pubmed-meshheading:20458483-Follow-Up Studies,
pubmed-meshheading:20458483-Humans,
pubmed-meshheading:20458483-Hypertension,
pubmed-meshheading:20458483-Indoles,
pubmed-meshheading:20458483-Kidney Neoplasms,
pubmed-meshheading:20458483-Male,
pubmed-meshheading:20458483-Mouth Diseases,
pubmed-meshheading:20458483-Practice Guidelines as Topic,
pubmed-meshheading:20458483-Protein Kinase Inhibitors,
pubmed-meshheading:20458483-Pyrroles,
pubmed-meshheading:20458483-Risk Assessment,
pubmed-meshheading:20458483-Skin Diseases,
pubmed-meshheading:20458483-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
|
| pubmed:affiliation |
Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
|
| pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|